Overexpression of Elastin Affects the Protease to Anti-Protease Balance and Protects Mice from Colitis

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Secretory leukocyte protease inhibitor and elafin/trappin-2: versatile mucosal antimicrobials and regulators of immunity.

  2010cited by this paper
• Plasma Neutrophil Elastase and Elafin Imbalance Is Associated with Acute Respiratory Distress Syndrome (ARDS) Development

  2009cited by this paper
• Regulation of tissue homeostasis by NF-κB signalling: implications for inflammatory diseases

  2009cited by this paper
• Protease-activated receptor-2 activation: a major actor in intestinal inflammation

  2008cited by this paper
• Role of the intestinal barrier in inflammatory bowel disease.

  2008cited by this paper
• Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating antiinflammatory progranulin.

  2008cited by this paper
• Proteinase-activated receptors (PARs) in infection and inflammation in the gut.

  2008cited by this paper
• Helicobacter pylori induces an antimicrobial response in rhesus macaques in a cag pathogenicity island-dependent manner.

  2008cited by this paper
• Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators

  2008cited by this paper
• Microbial influences in inflammatory bowel diseases.

  2008cited by this paper
• Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn’s disease

  2007cited by this paper
• Role for protease activity in visceral pain in irritable bowel syndrome.

  2007cited by this paper
• Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents.

  2006cited by this paper
• A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

  2006cited by this paper
• Elafin Prevents Lipopolysaccharide-induced AP-1 and NF-κB Activation via an Effect on the Ubiquitin-Proteasome Pathway*

  2006cited by this paper
• CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT

  2005cited by this paper
• Reduced Paneth cell alpha-defensins in ileal Crohn's disease.

  2005cited by this paper
• A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis.

  2005cited by this paper
• Proteinase‐activated Receptor‐1 is an Anti‐Inflammatory Signal for Colitis Mediated by a Type 2 Immune Response

  2005cited by this paper
• PAR2 activation alters colonic paracellular permeability in mice via IFN‐γ‐dependent and ‐independent pathways

  2004cited by this paper
• Adenoviral Gene Delivery of Elafin and Secretory Leukocyte Protease Inhibitor Attenuates NF-κB-Dependent Inflammatory Responses of Human Endothelial Cells and Macrophages to Atherogenic Stimuli1

  2004cited by this paper
• Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability

  2003cited by this paper
• Regulation of Pulmonary and Systemic Bacterial Lipopolysaccharide Responses in Transgenic Mice Expressing Human Elafin

  2003cited by this paper
• Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2.

  2002cited by this paper
• Targeted overexpression of elafin protects mice against cardiac dysfunction and mortality following viral myocarditis.

  1999cited by this paper
• Elafin (elastase‐specific inhibitor) has anti‐microbial activity against Gram‐positive and Gram‐negative respiratory pathogens

  1999cited by this paper
• Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters

  1998cited by this paper
• Elafin/elastase-specific inhibitor in bronchoalveolar lavage of normal subjects and farmer's lung.

  1996cited by this paper
• SKALP/elafin: an elastase inhibitor from cultured human keratinocytes. Purification, cDNA sequence, and evidence for transglutaminase cross-linking.

  1993cited by this paper
• Purification and characterization of elastase-specific inhibitor. Sequence homology with mucus proteinase inhibitor.

  1991cited by this paper
• Elafin is a potent inhibitor of proteinase 3.

  1991cited by this paper
• Historical aspects of inflammatory bowel disease.

  1988cited by this paper

• Crohn’s disease proteolytic microbiota enhances inflammation through PAR2 pathway in gnotobiotic mice

  2023influential citation
• The emerging roles of bacterial proteases in intestinal diseases

  2023influential citation
• The Effect of Serine Protease Inhibitors on Visceral Pain in Different Rodent Models With an Intestinal Insult

  2022cites this paper
• Human neutrophil IL1β directs intestinal epithelial cell extrusion during Salmonella infection

  2022cites this paper
• The double-edged sword of gut bacteria in celiac disease and implications for therapeutic potential

  2022cites this paper
• Neutrophils in Intestinal Inflammation: What We Know and What We Could Expect for the Near Future

  2022cites this paper
• Clinical Significance of Serum Elafin in Children with Inflammatory Bowel Disease

  2022cites this paper
• Encouraging Tactics with Genetically Modified Probiotics to Improve Immunity for the Prevention of Immune-Related Diseases including Cardio-Metabolic Disorders

  2022cites this paper
• Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis

  2021cites this paper
• Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease‐activated receptor 1‐ and protease‐activated receptor 4‐dependent mechanism

  2018cites this paper
• WAPing Out Pathogens and Disease in the Mucosa: Roles for SLPI and Trappin-2

  2013cites this paper